Grant: Proof of Principle Program Phase I - Drug Development
McGill University
$158,850.00
Discovery and uses of a new class of small molecule inhibitors of tyrosine phosphatases.
FY 2009-10
Summary
Protein tyrosine phosphatases (PTP) are proteins that are very important in the normal function of various human cells. However, in several diseases such as severe inflammation, diabetes, cancer, neurodegenerative diseases and spinal cord injuries, some of these proteins contribute to the initiation, progression and pathology of these syndromes. Towards finding new treatments and cures for these ailments, this project aims at improving and refining several novel molecules that we characterize as being able to inhibit these PTPs. Our objective is to develop further these inhibitors towards their subsequent applications in the clinic for the treatments of a variety of human diseases.
Department
Program
Proof of Principle Program Phase I - Drug Development
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
206034
Name
Tremblay Michel L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Discovery and uses of a new class of small molecule inhibitors of tyrosine phosphatases.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$158,850
Cihrequipment2
$0
Programname2
Proof of Principle Program Phase I - Drug Development
Keyworddelim
Animal Model; Cell Based Assay; Compound Screening; Inhibitors; Small Molecules; Tyrosine Phosphatase
Abstract
Protein tyrosine phosphatases (PTP) are proteins that are very important in the normal function of various human cells. However, in several diseases such as severe inflammation, diabetes, cancer, neurodegenerative diseases and spinal cord injuries, some of these proteins contribute to the initiation, progression and pathology of these syndromes. Towards finding new treatments and cures for these ailments, this project aims at improving and refining several novel molecules that we characterize as being able to inhibit these PTPs. Our objective is to develop further these inhibitors towards their subsequent applications in the clinic for the treatments of a variety of human diseases.
Competitiondate
201003
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tremblay, Michel L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $158,850~ $0~